MediWound Ltd. (MDWD)
16.28
0.11 (0.68%)
At close: Apr 03, 2025, 3:59 PM
15.20
-6.63%
After-hours: Apr 03, 2025, 04:58 PM EDT
Company Description
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel and bio-therapeutic solutions for tissue repair and regeneration.
It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.
The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma.
MediWound Ltd. was founded in 2000 and is headquartered in Yavne, Israel.
MediWound Ltd.
| Country | IL |
| IPO Date | Mar 20, 2014 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 111 |
| CEO | Ofer Gonen B.Sc. |
Contact Details
Address: 42 Hayarkon Street Yavne, IL | |
| Website | https://www.mediwound.com |
Stock Details
| Ticker Symbol | MDWD |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001593984 |
| CUSIP Number | M68830104 |
| ISIN Number | IL0011316309 |
| Employer ID | 00-0000000 |
| SIC Code | 2833 |
Key Executives
| Name | Position |
|---|---|
| Ofer Gonen B.Sc. | Chief Executive Officer |
| Dr. Shmulik Hess Ph.D. | Chief Operating Officer & Chief Commercial Officer |
| Hani Luxenburg | Chief Financial Officer |
| Barry J. Wolfenson | Executive Vice President of Strategy & Corporate Development |
| Dr. Ety Klinger MBA, Ph.D. | Chief Research & Development Officer |
| Dr. Lior Rosenberg M.D. | Co-Founder |
| Dr. Liron Gal | Executive Director of Manufacturing Science & Technology |
| Dr. Robert J. Snyder CWS, D.P.M., F.A.C.F.A.S., FFPM, M.B.A., M.Sc. | Chief Medical Officer |
| Yaron Meyer Adv. | Executive Vice President, General Counsel & Corporate Secretary |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 28, 2025 | 424B3 | Filing |
| Mar 19, 2025 | F-3 | Filing |
| Mar 19, 2025 | S-8 | Filing |
| Mar 19, 2025 | 20-F | Filing |
| Mar 19, 2025 | 6-K | Filing |
| Feb 12, 2025 | 6-K | Filing |
| Feb 11, 2025 | SCHEDULE 13G/A | [Amend] Filing |
| Jan 08, 2025 | 6-K | Filing |
| Dec 19, 2024 | 6-K | Filing |
| Dec 16, 2024 | 6-K | Filing |